T

Trevi Therapeutics
D

TRVI

3.11000
USD
-0.06
(-1.89%)
مغلق
حجم التداول
10,391
الربح لكل سهم
0
العائد الربحي
0
P/E
-8
حجم السوق
218,501,670
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأخبار
المقالات

العنوان: Trevi Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.